BackOmega Therapeutics Overview

Omega Therapeutics Other Current Liabilities

Track Omega Therapeutics's other current liabilities ($6.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$6.82M
2173.33% YoYΔ $6.52M vs prior year quarter

Peer trimmed avg / median

Loading

Omega Therapeutics Other Current Liabilities History

Loading

Omega Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Omega Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Omega Therapeutics (OMGA) FAQ

As of the most recent data (September 2024), OMGA shows a other current liabilities of $6.8M. That compares with $300K in the prior-year period — up 2173.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, OMGA's other current liabilities is now $6.8M (was $300K) — a 2173.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Omega Therapeutics is outperforming or lagging.

Tracking OMGA's other current liabilities over time shows whether Omega Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $6.8M That compares with $300K in the prior-year period — up 2173.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Omega Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $6.8M) with ownership activity and broader fundamentals.

Omega Therapeutics's other current liabilities is $6.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.